Page results
-
A new CAR T-cell therapy developed by scientists at UCL has fewer ‘toxic’ side-effects and is more durable, targeting and killing cancer cells for longer, concludes a Phase 1 clinical trial of patients at UCLH.
-
The National Paediatric Diabetes Audit (NPDA) is asking all children and young people (8-19 years) and parents/carers (of children under 8 years old) who have received diabetes care in the past 6 months, to fill in the survey.
-
UCLH NHS Foundation Trust has once again formed a partnership with the Business Design Centre in Islington to reopen a large-scale COVID-19 vaccination centre on site from Saturday 18 December.
-
A front page story and patient case study highlight SUMMIT Study early diagnosis outcomes.
-
University College London Hospitals (UCLH) is now administering new COVID-19 treatments for patients at highest risk in the community.
-
Having proton beam therapy: information for children aged 5-8 patient information page.
-
Having proton beam therapy: information for children aged 9-12 patient information
-
Having proton beam therapy: information for teenagers aged 13-17 patient information.
-
In a major study involving UCLH a third of people who took a new drug for treating obesity lost more than one-fifth of their total body weight.
-
Our vaccination centre at the Business Design Centre, Islington, closed on Monday 10 January.
File results
-
FOI/2024/05523 - Dabrafenib + Trametinib cancer treatment for metastatic and adjuvant melanoma/ lung/ colorectal cancer
-
FOI/2024/0527 - Treatment for renal cell carcinoma
-
FOI/2024/0528 - Open MRIs referrals for patient size/ spend on specialist bariatric equipment 2017-2024
-
FOI/2024/0529 - Medical Associate Professionals (MAPs) at Trust
-
FOI/2024/0530 - Radiology/ imaging examinations/ patient access to radiology images
-
FOI/2024/0532 - Patient treatment/ care/ consent
-
FOI/2024/0543 - Guidelines, policies for the treatment of obesity/ pathways for Tier 3 or Tier 4 weight management services
-
FOI/2024/0356 - Treatment with Durvalumab and Nivolumab for biliary tract/ non-small cell lung cancer
-
FOI/2024/0357 - Multiple myeloma treatments
-
FOI/2024/0360 - Radiology Information System (RIS) supplier/ contract/ staff details